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Abstract 
Objective:Atrial Fibrillation (AF) is associated with dementia.  If AF-related cognitive 
decline is driven by cerebral embolic events, thromboprophylaxis may impact on this.  
This systematic review assessed the association between cognitive impairment and 
AF thromboprophylaxis. 
Methods:Two independent reviewers searched CINAHL, EMBASE, MEDLINE, 
PsycINFO, Web of Science Core Collection, and Cochrane Library from inception 
until 12th November 2014.  Eligible studies compared AF thromboprophylaxis to 
control with an outcome measure of cognition or dementia.  Where data allowed, 
meta-analyses describing between-group differences in cognitive test scores or rates 
of incident dementia were performed.  
Results:Nineteen studies were eligible.  For two prospective studies (one RCT) 
comparing anticoagulation against antiplatelet therapy, change in Mini-Mental State 
Examination score from baseline to last follow-up (maximal duration:5.9 years) 
suggested a difference favouring anticoagulation (mean difference:0.90, 95% CI:0.29 
to 1.51), in keeping with a trend seen in the single RCT (mean difference 
MMSE:0.80. 95% CI:-0.07 to 1.67).  Pooled odds ratios suggested no association 
with incident dementia, comparing anticoagulant to antiplatelet therapy (two studies, 
OR:1.23, 95% CI:0.80 to 1.91) or no treatment (three studies, OR:0.89, 95%CI:0.47 
to 1.69). 
Conclusions:Our analyses show no definitive evidence of cognitive benefit or harm 
from anticoagulation.  We demonstrated a potential benefit of anticoagulation in 
comparison to antiplatelet over time. Larger-scale studies with longer follow-up are 
needed to determine the true cognitive impact of AF thromboprophylaxis.  
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Key points 
• Atrial fibrillation (AF) is associated with dementia, the mechanism of which is 
not fully understood.   
• Published data do not prove any decrease (or increase) in incident dementia 
over time in patients anticoagulated versus those treated with antiplatelet or 
placebo.   
• The clinical significance of improvements in cognition comparing those treated 
with anticoagulation and antiplatelet is uncertain.   
• Data are not definitive and future AF studies and registries should collect 
cognitive outcomes. 
  
 4 
Introduction 
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, affecting 2% 
of the European population; rising to between 10%–17% of those aged over 80 
years.[1]  AF is associated with substantial morbidity and mortality, predominantly 
driven by cardioembolism.[2]  Other adverse health effects of AF have been 
suggested including an association with dementia.[3]  
 
The pathophysiological mechanisms underlying the cognitive effects of AF remain 
poorly understood.  Clinical stroke alone is not sufficient explanation.[3]   A possible 
mechanism of action is via sub-clinical cerebral infarcts exerting a cumulative effect 
on cognition.  Occult infarcts in a distribution suggesting embolic aetiology are at 
least twice as common on brain imaging in AF patients as they are in sinus rhythm.[4]  
Other processes may also play a role, global cerebral hypoperfusion could contribute 
and there is the possibility of confounding from a shared factor that for example 
alcohol, smoking and obesity.  These concepts are not exclusive and cognitive 
decline in AF may be related to all of these or other, as yet undetermined, 
mechanisms.[5,6,7]   
 
There are potent, evidence-based treatments to prevent AF-related cardioembolism, 
for example vitamin K antagonists (VKAs) or the non-VKA oral anticoagulants 
(NOACs).  It is possible that such treatments could reduce cognitive decline, by 
reducing (sub-clinical) infarct burden. Cognitive efficacy of AF thromboprophylaxis 
should not be assumed, anticoagulation is unlikely to impact on non-embolic 
mechanisms and in the context of amyloid angiopathy and other neuropathological 
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changes of dementia syndromes, anti-thrombotics could contribute to, or accelerate, 
cognitive decline by precipitating intracerebral bleeding. 
 
We explored the cognitive effects of AF thromboprophylaxis using systematic review 
and meta-analysis.  
 
Methods 
We followed Meta-Analysis of Observational Studies in Epidemiology (MOOSE) 
guidance in conduct and reporting.  We registered our review protocol with the 
PROSPERO database [CRD42014015073].  All aspects of the review (title searching, 
data extraction, quality assessment) were carried out by two independent reviewers 
and results compared and agreed upon through discussion.    
  
Our primary objective was to offer a synthesis of the available data describing the 
cognitive effects of treatments to reduce cardioembolism in AF.  
 
The following subgroup analyses were planned if data allowed: 
• Effects of treatment in paroxysmal versus permanent/persistent AF patients. 
• Effects of antithrombotic treatment in those with previous stroke compared 
with no history of stroke. 
• Effects of antithrombotic treatment on vascular dementia rates compared to 
other dementias. 
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Criteria for considering studies for this review:We created inclusion/exclusion 
criteria for the review based on the PICOS (participants; interventions; controls; 
outcomes and study type) method.   
 
Participants:Our population of interest was any adult, human with AF (atrial 
fibrillation and/or atrial flutter).  We included all AF diagnoses including permanent, 
persistent and paroxysmal.  We operated no exclusions based on age, time since 
diagnosis or treatment received.  All other ventricular or supraventricular arrhythmias 
were excluded. 
 
Interventions:Interventions of interest were any treatment used primarily to prevent 
cardioembolism in AF. We designed our search to focus on anticoagulation and 
antiplatelet therapy but included search terms around mechanical interventions, for 
example, left atrial appendage occlusion devices.  We will refer to these as 
“treatments”, although for observational cohorts “exposed” could be a better term.    
 
Controls:Comparators included "placebo" control arms and also comparison with 
another active intervention, for example, antiplatelet versus anticoagulation. 
 
Outcomes:Our co-primary outcomes of interest were any quantitative measure of 
cognition or clinical diagnosis of dementia.  For cognitive assessments, we included 
those studies that described outcomes using a validated cognitive assessment tool.  
For clinical diagnosis, we included any diagnosis of dementia or related syndromes 
made using a recognised classification system.  We did not include papers reporting 
only surrogate measures such as neuroimaging. 
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Study type:We sought to include all relevant Randomised Controlled Trials (RCTs); 
these were trials with a primary cognitive endpoint or trials that included cognitive 
data as a secondary endpoint or as a sub-study.  We also included observational 
studies and quasi-randomised trials relevant to the study question.  We excluded 
case reports and case series, which for the purposes of this review we defined as 
studies having less than 10 participants.  We operated no exclusions based on 
language. 
 
Search strategy:We created a sensitive search strategy based around concepts of 
AF, cognitive decline/dementia and thromboprophylaxis.  Where available we used 
validated search strings, supplemented with MeSH terms and other controlled 
vocabulary.  We searched various, multidisciplinary electronic databases from 
inception until 12th November 2014 inclusive: Central (Cochrane Library), CINAHL 
(EBSCO); EMBASE (OVID); MEDLINE (OVID); PsycINFO (EBSCO); Web of 
Science Core Collection (Thomson Reuters).(Supplementary materials).  
 
We performed citation searches of relevant papers and reviews in this field, “back” 
searching the references of papers of interest and also “forward” searching to find 
other papers citing the paper of interest. We contacted key authors who had 
published in the field and authors of included studies for relevant unpublished data. 
 
As a test of external validity of our search strategy, two exemplar papers that were 
known to be relevant to our study question were selected by a team member (TQ) 
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independent of the search process.  We assessed whether our search identified 
these papers. 
 
Data extraction and synthesis:Titles from all database searches were collated, de-
duplicated and screened for relevance (EndNote version X7, Thomson Reuters, 
Philadelphia, USA).  For initial title searching we used a previously validated 
technique where one reviewer, trained in systematic review (PM), assessed all titles 
generated while another experienced systematic reviewer (TQ) assessed a random 
selection of 1,000 of these titles.[8]  We compared titles selected, to assess whether 
the focussed review (TQ) included any titles not included in the long-list review (PM).   
 
Potentially relevant titles had abstracts screened and full papers as required were 
independently screened by two reviewers (PM, DL [experienced reviewer]). Data 
was extracted to a study specific proforma, piloted on two relevant papers and 
refined as necessary.(Supplementary materials) 
 
Two independent assessors (PM, TQ) used the Cochrane Risk of Bias tool for 
randomised controlled trials and the Risk of Bias Assessment Tool for Non-
randomized Studies (RoBANS) to assess those studies providing quantitative data.[9]  
We modified the anchoring statements to suit our specific research 
question.(Supplementary materials)  Both assessments included seven different 
categories covering domains of selection bias, confounding, measurement of 
exposure, blinding, attrition bias, reporting bias and generalizability.  Domains were 
assessed individually and rated, “High risk”, “Low risk” or “Unclear risk”. 
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Statistical analyses:We anticipated that outcomes of interest would be described 
as scores on multi-domain cognitive tests or rates of dementia diagnosis.  Therefore, 
we pre-specified two primary analyses: 
a)Comparison of temporal change in cognitive score between treatment arms from 
baseline to point of longest follow-up. 
b)Comparison of rates of incident dementia/cognitive impairment between treatment 
arms. 
 
We described absolute scores on cognitive tests for each treatment arm.  For 
prospective studies we described scores at baseline and follow up(s).  We calculated 
mean differences in scores from baseline to final follow up and then described 
summary between group change over time.   
 
For prospective studies describing rates of incident diagnoses at a specific time point, 
we calculated rates of development of a cognitive outcome (including syndromes of 
cognitive impairment and dementia) comparing treatment arms.  We pooled these 
data to give a summary odds ratio for incident cognitive impairment.    
 
To make greatest use of available data we included mixed study designs in pooled 
analyses (RCTS and observational cohorts) and performed sensitivity analyses 
restricted to single study methodologies.   
 
We tested for statistical heterogeneity with the I² statistic and qualitatively through 
visual analysis of forest plots.  We present both fixed and random effects summary 
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data.  We assessed publication bias using a “funnel plot” technique.  All analyses 
used Comprehensive Meta-Analysis software (CMA, Version 2, Biostat Inc). 
 
Results 
We obtained 8,993 references from the initial electronic database search and 
reviewed abstracts and/or full text of 234 papers.(Figure 1)  Of these, 19 studies 
(n=15,876 participants) were suitable for inclusion [10-28] (five were extended 
abstracts, supplemented, where possible, by additional data from authors [23-
27]).(Table 1)   
 
The internal validity of title searching process was confirmed as no titles from 
focused review were missed in the full review.  The external validity of the search 
strategy was confirmed, as both of the pre-identified papers were included in the final 
selection.[10,14] 
 
Narrative Review of Included Studies:Included studies were heterogeneous in 
terms of sampling, outcomes assessment and study design.  Included data were 
from RCTs, observational cohorts, with the majority of papers from cross-sectional 
studies (weaker forms of evidence). Studies were from a range of international 
centres and year of publication ranged from 1998 to 2015.(Table 1) 
 
Of five RCTs identified, only one had cognitive data suited to our proposed 
analysis.[11]  In this study, the Birmingham Atrial Fibrillation Treatment of the Aged 
(BAFTA) study, older adults were randomised to warfarin (target International 
Normalised Ratio:2-3) or aspirin therapy (75mg/d) over a 33-month period in an 
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open-label, blinded endpoint design.  This study found no evidence that 
anticoagulation was superior to antiplatelet therapy in the prevention of cognitive 
decline or incident dementia.  There was a suggestion of less cognitive decline with 
anticoagulation in the longer term, but there was substantial attrition.    
 
Three other RCTs collected data on antithrombotic medication and cognition; the 
cognitive sub-study of the Apixaban Versus Acetylsalicylic acid to Prevent Strokes 
(AVERROES) trial has not yet released cognitive data [23]; a post-hoc sub-study of 
the Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular 
Events (ACTIVE-W) study reported association between time in therapeutic range 
and cognitive scores but did not provide cognitive scores by treatment arm.[13]  
Similarly, a single-centre study of warfarin versus aspirin provided only aggregate 
cognitive data.[14]   
 
One RCT compared cognitive outcomes following different methods of left atrial 
catheter ablation, and showed no significant difference in cognition between differing 
ablation methods.[12]   
 
We identified seven prospective observational studies.[15,16,20,22,24-6]  Across 
RCT and observational cohorts, timing of assessments varied (Table 1) there was 
substantial attrition at longer follow-ups.  Of the studies not included in meta-analysis, 
one described participants with AF from two large cardiovascular RCTs (Ongoing 
Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial 
[ONTARGET] and Telmisartan Randomised Assessment Study in ACE Intolerant 
Subjects with Cardiovascular Disease [TRANSCEND]) and reported that 
 12 
antithrombotic medication did not modify the association between AF and a 
composite outcome of change in cognitive score, incident dementia or admission to 
institutional care.[15]  Analysis of AF in the Atherosclerosis Risk in Communities 
(ARIC) study reported greater cognitive decline in subjects with AF, particularly 
where associated with neuroimaging evidence of stroke [16]; similar associations 
were reported in an Italian study.[17]  Both were unsuitable for quantitative analysis 
as data on medication and cognitive scores were described in aggregate and not by 
treatment arm. 
 
We found seven cross-sectional studies describing association between cognition 
and thromboprophylaxis.[10,17,18,19,21,27,28] Two studies [19,27] were combined 
with baseline data from prospective studies to offer a “snapshot” of the cross-
sectional association between anticoagulation and cognition.(Supplementary 
materials).   
 
Quantitative analysis:Ten studies had suitable quantitative data, comprising one 
RCT [11] and four prospective, observational studies [20,24-26] (total 
participants:7,063).  Studies were comparisons of antithrombotic or anticoagulant 
therapy versus antiplatelet therapy or no treatment.  No studies looked at surgical 
procedures.  The outcome measures were dementia/cognitive impairment or scores 
on Folstein’s Mini Mental State Examination (MMSE).  Funnel plot suggested no 
major publication bias.(Supplementary materials) 
 
Where studies offered prospective follow-up, temporal decline in MMSE was less for 
those anticoagulated compared to those receiving antiplatelet therapy (mean 
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difference MMSE:0.90, 95%CI:0.29 to 1.51).  This result is in keeping with the trend 
seen in the single RCT (mean difference MMSE:0.80. 95%CI:-0.07 to 1.67).    
 
There was no between-group difference in incident dementia/cognitive impairment 
across studies comparing anti-thrombotic/anticoagulant to control (overall summary 
odds ratio:1.11 (95%CI:0.77-1.60).  In subgroup analyses there was no difference in 
incident cognitive syndromes comparing anticoagulant and antiplatelet (two studies, 
summary odds ratio:1.23 (95%CI:0.79-1.92 [odds ratio:1.46 (0.83-2.58) on sensitivity 
analysis, removing the RCT]) or anticoagulant versus no treatment/placebo (three 
studies, summary odds ratio:0.89 (95%CI:0.47-1.69)).(Figure 2)  
 
Included studies did not contain sufficient information to allow for any of our pre-
specified subgroup analyses.(Supplementary materials)  
 
Risk of Bias and Generalisability Assessment for Included Studies:Using our 
assessment tools, all included studies had potential risk of bias.  The main 
methodological issues were around blinding; only one study had sufficient blinding 
[20], and robustness of measures of exposure and outcomes, four studies11,,20,24,25 
had unclear or poor measures of dementia and/or AF diagnosis, such as self-
reporting.[11,20,24,25](Table 2) 
 
Discussion 
We found few studies evaluating the cognitive consequences of AF 
thromboprophylaxis and where data were available, there was substantial risk of bias.  
Prospective data were suggestive of a modest protective cognitive effect from 
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anticoagulation in AF in the longer term but we found no decrease in rates of incident 
dementia.   
 
We can speculate on the reasons for these results.  Detecting change in incident 
dementia rates probably requires larger sample sizes and longer follow-up than 
studies describing change in a surrogate cognitive measure.  Thus even with meta-
analysis, sample sizes may be too small to detect modest effects.  It may also be 
that the cognitive decline associated with AF is not solely a result of cardioembolism 
(various other mechanistic explanations have been postulated).[5-7] A degree of 
cognitive harm, for example from cerebral amyloid angiopathy related bleeding, 
remains possible. 
 
The data that informed our analyses are liable to a variety of biases.  Populations 
were not matched, with those prescribed anticoagulants having higher baseline 
cognitive scores.  A degree of selection bias, wherein those with better cognition, or 
at greater risk of stroke, are more likely to be prescribed warfarin, seems possible 
and the resulting cognitive trajectories may differ independent of antithrombotic 
agent used.  The ideal study design would be a RCT in a cohort with AF, free from 
dementia at baseline.  We found only one full published paper that used this 
method.[11]  This study reported no significant difference in incident dementia 
comparing warfarin and aspirin but was probably underpowered for this secondary 
outcome. 
  
We set no time limits on our study inclusion and we note that clinical guidance for AF 
has changed over time.  In older studies, the majority of patients with AF received no 
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thromboprophlaxis or were prescribed antiplatelets; the latter treatment (as 
monotherapy) is no longer recommended for stroke thromboprophylaxis in AF due to 
limited efficacy.[29]  Collating these older datasets with large numbers on no 
treatment or aspirin offered the potential to describe the “natural history” of cognitive 
decline in AF patients free from treatment that could be compared with VKA data.  
Unfortunately, across the relevant studies, sample sizes were modest or data were 
not available in a format that allowed such an analysis.  The anticoagulant studied 
was predominantly warfarin.  We recognise the increasing use of NOACs and these 
agents may have a differing cognitive profile.  As the NOACs have lower incidence of 
intracerebral haemorrhage, plausibly they may have greater net cognitive benefit.    
 
It could be argued that our research question is redundant, as in contemporary 
practice, the majority with AF will require anticoagulation for stroke prevention 
regardless of any potential added cognitive benefit.  However, had we demonstrated 
beneficial cognitive effects of thromboprophlaxis this could have expanded the 
population who may benefit from anticoagulation and may have increased 
anticoagulant prescriptions.  We recognise that, despite compelling evidence of 
efficacy, anticoagulation remains under-prescribed particularly in older adults.[30]  
There were plausible reasons to think that intracerebral bleeding due to 
anticoagulation may worsen cognitive decline, and indeed one paper in our review 
demonstrated such an effect.[24]  However, we found no evidence of worsening 
cognitive decline with anticoagulation in the pooled analysis. This is an important 
finding and supports the use of anticoagulation in older adults.   
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The major limitation of our included studies was in their study design, with only one 
RCT included.  Methodological limitations were highlighted by our quality 
assessment tool. Generalisability was variable and participants included in studies 
may not be equivalent to patients seen in practice, several studies did not employ 
blinded outcome assessments and there was substantial attrition in longitudinal 
studies.  This is of particular relevance, as participants with cognitive issues may be 
more likely to be lost to follow-up.  We included a variety of cognitive diagnoses and 
tests as our outcomes of interest, this was necessary to allow for pooled analyses.  
We recognise that cognitive test scores alone are not synonymous with clinical 
dementia and that within a label of clinical cognitive impairment there can be 
substantial variation in severity. 
 
We used a comprehensive search strategy.  In designing our search, we limited to 
drugs and procedures that directly reduce cardioembolism.  Maintenance of sinus 
rhythm may prevent cardioembolism but to keep our review focussed we did not 
specifically search for cardioversion interventions.  We followed best practice in 
conduct and reporting.  All papers were quality assessed using a robust method 
tailored to our specific study question.  We recognise the substantial heterogeneity in 
the included studies and need to be cautious in our interpretation of pooled data.  
 
Our review does not suggest a need for change in practice, those with AF at risk of 
stroke should continue to be anticoagulated.  However, our review highlights an 
important evidence gap.  There is sufficient signal of a beneficial cognitive effect 
from anticoagulation to justify further study.  Our assessment of risk of bias and 
reporting of important features such as incident stroke and AF risk stratification 
 17 
highlight limitations in previous studies and may be helpful in the design, conduct 
and reporting of future studies.  Future studies of AF patients should include serial 
measures of cognition to provide data on the impact of thromboprophylaxis on 
cognitive function; studies should also include data on stroke and stroke risk 
stratification.  We recognise that a patient who warrants anticoagulation should not 
be randomised to placebo or antiplatelet.  Studies could look at “low risk” groups or 
compare NOACs which still have a portfolio of research and development. This is 
particularly important as a potential reduction in dementia risk may influence clinical 
decision-making regarding initiation of these agents in older, frailer people with AF.   
 
In summary, we were unable to provide definitive evidence of a beneficial cognitive 
effect of thromboprophylaxis for AF patients.  Available data suggest that 
anticoagulant therapy may be associated with reduced cognitive decline over time, 
although the clinical significance is uncertain.  Our findings need to be interpreted in 
the context of the included studies, as these had substantial risk of bias and even 
pooled results may have been underpowered.  
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Table 1: Characteristics of included studies  
Author/ Year Setting Recruitment N included 
Cognitive 
Measure 
Assessment 
timing 
Intervention Control 
Randomised Controlled Trials 
Mavaddat 2014 [11] 
England/ 
Wales 
C 973 
MMSE, 
Dementia 
9/12, 21/12, 33/12 Anticoagulant Antiplatelet 
Haeusler 2013 [12] Germany H 37 NPB 9/12 
Left atrial catheter 
ablation 
Left atrial catheter 
ablation 
O’Donnell 2011 [23] 
International C 1184 
m-MoCA, 
DSS 
unclear Anticoagulant Antiplatelet 
Flaker 2010 [13] Global C 2510 MMSE 16/12 Anticoagulant Antiplatelet 
Rash 2007 [14] England H 75 MMSE 12/12 Anticoagulant Antiplatelet 
Cross-Sectional Comparisons 
Ball 2013 [21] Australia H 260 
Cognitive 
impairment 
N/A Anticoagulant Antiplatelet 
 
Cannon 2015 [27] 
Scotland H 61 MMSE N/A Anticoagulant Antiplatelet 
 
Formiga 2009 [19] 
Spain H 84 MMSE N/A Anticoagulant Antiplatelet 
 25 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gaita 2013 [17] Italy H 270 NPB N/A Anticoagulant Antiplatelet 
Maes 2014 [18] Belgium H 773 
Cognitive 
Disorders 
N/A Anticoagulant No Treatment 
O’Connell 1998 [10] England C 81 MMSE N/A Antiplatelet No Treatment 
Puccio 2009 [28] Italy H 42 NPB, MMSE N/A Anticoagulant Antiplatelet 
Prospective Observational Cohorts 
Chen 2014 [16] USA C 48 NPB 12/12 Anticoagulant Antiplatelet 
Liao 2013 [25] Taiwan C 5,221 Dementia 71/12 
Anticoagulant Antiplatelet 
Antithrombotic* No Treatment 
Meranus 2013 [24] USA H 420 Dementia 42/12 
Anticoagulant 
No Treatment 
Antithrombotic* 
Marzona 2012 [15] Global C 3,068 MMSE 56/12 Antithrombotic No Treatment 
 
Franco 2012 [26] 
Italy H 191 MMSE 48/12 Anticoagulant Antiplatelet 
 
Park 2007 [22] 
England C 119 MMSE 12/12, 36/12 Anticoagulant Antiplatelet 
 
Barber 2004 [20] 
Scotland C 258 Dementia 36/12 Anticoagulant No Treatment 
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*The use of both anticoagulant and antiplatelet therapy 
 
CDR=Clinical Dementia Rating; dementia=clinical diagnosis of dementia; DSS=Digit Symbol Substitution; MMSE=Mini Mental State Exam; m-
MoCA=modified Montreal Cognitive Assessment; NPB=neuropsychological battery; RCT=Randomised Controlled Trial 
H= Hospital-based 
C= Community-based  
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Table 2:Risk of Bias Assessment Table 
 
 
 
 
 
 
  
Papers Selection 
Bias 
Confounding 
variables 
Measurement 
of exposure 
Blinding Attrition 
Bias 
Reporting 
Bias 
Generalizability 
Liao 2013 Low risk Low risk High risk Unclear Low risk Unclear Low risk 
Meranus 
2013 
Low risk Low risk High risk High risk Low risk Unclear High risk 
Franco 
2012 
Low risk Low risk Low risk Unclear High risk Unclear High risk 
Barber 
2004 
Low risk Low risk Unclear Low risk High risk High risk Low risk 
Randomised controlled trials 
Papers Random 
Sequence 
Generation 
Allocation 
Concealment 
Blinding of 
Participants 
Blinding 
of 
Outcome 
Reporting 
Bias 
 
Selective 
Reporting 
Generalizability 
Mavaddat 
2014 
Low risk High risk High risk High risk High risk Low risk High risk 
Figure 1: PRISMA flow diagram detailing search  
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Figure 2: Forest plot of odds ratio for developing dementia/cognitive impairment 
comparing anticoagulants and other therapy 
 
 
 
Included data are from prospective cohorts, other than Mavaddat which is a RCT.  
Sensitivity anlayses removing the RCT are presented in the text.  
 
